Dr. Reddy's Active Pharmaceutical Ingredients
Dr. Reddy's API business is the Active Pharmaceutical Ingredients division of Dr. Reddy's Laboratories, supplying 250+ APIs to global generic drug manufacturers across 80+ countries via 8 cGMP sites in India, Mexico, and the UK, with integrated CDMO services through subsidiary Aurigene.
- Company typePublic
- Founded1984
- HeadquartersHyderabad, India
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dr. Reddy's Active Pharmaceutical Ingredients does
Dr. Reddy's Active Pharmaceutical Ingredients is the API manufacturing and supply division of Dr. Reddy's Laboratories Ltd., a publicly traded pharmaceutical company (BSE/NSE) headquartered in Hyderabad, India, founded in 1984. The API business produces and supplies more than 250 active pharmaceutical ingredients to generic drug manufacturers across 80+ countries, backed by 2,000+ Drug Master Files (DMFs) filed globally. The division operates 8 cGMP-compliant manufacturing facilities (6 in India, 1 in Mexico, 1 in the UK), all of which have undergone inspection by major regulatory agencies including the US FDA.
The business is organized around four core offerings: (1) API Solutions, the core commercial manufacturing and supply franchise; (2) Generic Formulations, sold B2B to other drug makers; (3) Strategic Alliances, encompassing licensing and technology transfer arrangements with innovator pharma companies; and (4) Discovery & CDMO services delivered through Aurigene, a subsidiary formed in 2020 that consolidated the parent company's discovery, development, and contract research assets. Aurigene also operates the Aurigene.AI platform, which combines generative AI, predictive modeling, computational chemistry, and CADD/bioinformatics tools, and is supported by a virtual compound library of more than 12 billion molecules.
Revenue is generated through B2B supply agreements with generic formulation manufacturers, licensing royalties, technology-transfer fees, and CDMO contracts. Notable commercial relationships include manufacturing and supply arrangements with Gilead Sciences (remdesivir), FUJIFILM and Global Response Aid (Avigan for COVID-19), and Industrial Promotion Services for the East African Combined Pharmaceutical Center in Kenya. The parent company reported approximately $3.8B in revenue; the API business is one of several operating segments alongside branded generics and biosimilars, and segment-level financials for the API division alone are not separately disclosed in the available data.
Dr. Reddy's Active Pharmaceutical Ingredients firmographics
Firmographics- Name
- Dr. Reddy's Active Pharmaceutical Ingredients
- Legal name
- Dr. Reddy's Laboratories Ltd.
- Website
- https://api.drreddys.com
- Company type
- Public
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Dr. Reddy's API business is the Active Pharmaceutical Ingredients division of Dr. Reddy's Laboratories, supplying 250+ APIs to global generic drug manufacturers across 80+ countries via 8 cGMP sites in India, Mexico, and the UK, with integrated CDMO services through subsidiary Aurigene.
- Ownership category
- akta.pro rank
Dr. Reddy's Active Pharmaceutical Ingredients industry classification
Industry- Product category
- Active Pharmaceutical Ingredients Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
Keywords
Where Dr. Reddy's Active Pharmaceutical Ingredients is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
Dr. Reddy's Active Pharmaceutical Ingredients business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- API Sales: Sale of Active Pharmaceutical Ingredients to generic formulations manufacturers across 80+ countries. The company offers 250+ affordable, high-quality APIs, focusing on first-to-market and hard-to-make products.
- Generic Formulations (B2B): Supply of finished products to partners for distribution and commercialization. Market-specific, customizable dossiers meet local regulatory requirements. Includes formulation, tech transfer, and pre-formulation supplies.
- Discovery & CDMO Services (Aurigene): Integrated services across key starting materials, intermediates, APIs, and finished dosage forms from lab to market. CRDMO services including contract manufacturing and drug discovery for global pharma and biotech companies.
- Strategic Alliances: In-licensing and out-licensing arrangements, tech transfer services, and strategic partnerships to expand portfolio and bring innovative treatments to market efficiently.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B API product pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Dr. Reddy's Active Pharmaceutical Ingredients product offering
Product offeringCore offering
Dr. Reddy's API business manufactures and supplies high-quality, affordable Active Pharmaceutical Ingredients (APIs) to generic formulations manufacturers in 80+ countries. The company offers 250+ APIs with focus on first-to-market and hard-to-make molecules, supported by cGMP (ICH Q7) compliant manufacturing across 8 sites globally (6 in India, 1 in Mexico, 1 in UK) and 2,000+ Drug Master Files filed worldwide.
Product overview
Dr. Reddy's API business is a leading manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) operating as a multi-product pharmaceutical company. The core offering is API Solutions - a portfolio of 250+ high-quality APIs supplied to generic formulations manufacturers across 80+ countries. Complementing the core API business are four additional offerings: Generic Formulations (B2B) for finished product supply, Strategic Alliances for licensing and tech transfer services, Discovery & CDMO (Aurigene) for contract development and manufacturing, and Aurigene.AI for AI-driven drug discovery services. The company operates 8 API manufacturing sites (6 in India, 1 in Mexico, 1 in UK) and has filed 2000+ DMFs globally.
Differentiator
Problem solved
Functional benefit
Brands
- Aurigene.AI: AI-driven drug discovery platform leveraging cutting-edge tools like CADD and bioinformatics, featuring virtual library of 12+ billion compounds called Aurimine
- Aurigene Discovery & CDMO
- XCEED
Products and services
- API Solutions A portfolio of 250+ high-quality, affordable Active Pharmaceutical Ingredients (APIs) supplied to leading generic formulations manufacturers across 80+ countries, with focus on first-to-market and hard-to-make molecules. Customers include pharmaceutical companies needing API supply for commercial and R&D purposes.
- Generic Formulations (B2B) B2B formulations business supplying finished pharmaceutical products to distribution partners for commercialization in markets where Dr. Reddy's has no direct presence. Includes market-specific customizable dossiers meeting local regulatory requirements, along with formulation, tech transfer, and pre-formulation supplies.
- Strategic Alliances Strategic in-licensing and out-licensing services with comprehensive tech transfer capabilities enabling faster development, local manufacturing, and regulatory success for global pharma partners. Includes partnerships to bring innovative treatments to market efficiently.
- Discovery & CDMO (Aurigene) Contract Research, Development and Manufacturing Organization (CRDMO) subsidiary offering integrated services across key starting materials, intermediates, APIs, and finished dosage forms from lab to market, serving global pharma and biotech companies.
- Aurigene.AI AI-driven drug discovery platform integrating predictive, generative, and computational models with a validated compound database to streamline candidate identification for global pharma and biotech partners.
Quantifiable outcome
- First company to receive Health Canada marketing authorization for generic Semaglutide Injection in Canada
- +2 more outcomes
Companies that use Dr. Reddy's Active Pharmaceutical Ingredients
Customer profileSegments4 records
Ideal customer profiles3 records
Dr. Reddy's Active Pharmaceutical Ingredients technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Dr. Reddy's Active Pharmaceutical Ingredients partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Lenacapavir License PartnercoreBold Leap for Global HIV Prevention: Lenacapavir Agreement Signed. Partnership to advance global access to lenacapavir for HIV treatment and prevention.
- Industrial Promotion Services (IPS)coreStrategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya. This partnership aims to strengthen pharmaceutical manufacturing capabilities in East Africa through technology transfer and capacity building.
- FUJIFILM and Global Response AidcorePartnership with FUJIFILM and Global Response Aid for Avigan (favipiravir), a potential treatment for COVID-19. Dr. Reddy's developed Redyx formulation under license from Gilead.
- Aurigene (Subsidiary of Dr. Reddy's)coreAurigene is a subsidiary of Dr. Reddy's formed in 2020 by consolidating service businesses into a customer-centric organization. Offers integrated CRDMO services across key starting materials, intermediates, APIs, and finished dosage forms. Leverages Aurigene.AI platform with 12+ billion compound virtual library for drug discovery.
- Gilead SciencescoreLicensed from Gilead for Redyx (Remdesivir) formulation development. Dr. Reddy's developed the Redyx formulation under the license from Gilead for COVID-19 treatment.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Dr. Reddy's Active Pharmaceutical Ingredients competitors and assessment
Company assessmentBroad incumbents
- Cipla Limited: Cipla is a leading Indian pharmaceutical manufacturer with significant API production capabilities alongside its branded and generic finished-dose global business. Both companies leverage Indian manufacturing scale and global regulatory expertise to serve generic pharma customers worldwide.
- Sun Pharmaceutical Industries: Sun Pharma is India's largest pharmaceutical company with significant API manufacturing operations alongside a much larger branded and generic finished-dose business. Both companies share Indian heritage, USFDA-inspected facilities, and global generic customer reach, though Sun's portfolio is substantially broader.
- Lupin Limited: Lupin is a major Indian pharmaceutical company with integrated API and finished-dose operations serving global generic customers, particularly in the US and Europe. The company operates comparable cGMP manufacturing facilities and pursues a similar strategy of vertical integration between APIs and finished generics.
- Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with vertically integrated API production from its own manufacturing network supplying both internal and external customers. While headquartered in Israel rather than India, Teva competes with Dr. Reddy's for global generic API and finished-dose customers.
- Sandoz Group: Sandoz, recently spun out of Novartis, is one of the world's largest generics manufacturers with substantial API manufacturing capabilities. The company competes directly with Dr. Reddy's in supplying generic APIs and finished-dose products to global customers, particularly in Europe and the US.
Direct peers
- Divi's Laboratories: Divi's is a pure-play Indian API manufacturer and custom synthesis CDMO with comparable capabilities in complex small-molecule APIs and intermediates for global innovator and generic customers. Both companies operate cGMP-compliant Indian facilities supplying APIs into US/EU markets with similar regulatory filing depth.
- Aurobindo Pharma: Aurobindo Pharma is one of India's largest API and generic formulations manufacturers, with a comparable 200+ molecule API portfolio serving global generic customers. Both companies compete head-to-head in the global generic API market with similar USFDA-inspected manufacturing footprints and a focus on cost-efficient large-scale API production.
- Laurus Labs: Laurus Labs is an Indian-headquartered API manufacturer focused on high-quality APIs for antiretroviral, oncology, and cardiovascular therapies sold globally to generic and branded customers. The business model, customer profile, and end-market focus closely mirror Dr. Reddy's API franchise.
- Aarti Pharmalabs: Aarti Pharmalabs is an Indian API manufacturer with a comparable portfolio of high-quality APIs and intermediates serving global pharmaceutical customers. Both companies target similar therapeutic segments (cardiovascular, CNS, anti-infectives) and compete for global generic customer relationships.
Emerging players
- Piramal Pharma Limited: Piramal Pharma offers integrated CDMO services with capabilities in API manufacturing, formulations, and biologics development. While more diversified than Dr. Reddy's pure API business, Piramal's CDMO arm competes for similar global pharma partnership contracts and customer relationships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Dr. Reddy's Active Pharmaceutical Ingredients social profiles
Digital presenceDr. Reddy's Active Pharmaceutical Ingredients compliance and trust
Trust signalCompliance4 records
Dr. Reddy's Active Pharmaceutical Ingredients financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dr. Reddy's Active Pharmaceutical Ingredients leadership team
Management profileNumber of profiles
Dr. Reddy's Active Pharmaceutical Ingredients subsidiaries and ownership
Company hierarchySubsidiaries1 record
Dr. Reddy's Active Pharmaceutical Ingredients funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dr. Reddy's Active Pharmaceutical Ingredients M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dr. Reddy's Active Pharmaceutical Ingredients
What does Dr. Reddy's Active Pharmaceutical Ingredients do?
Dr. Reddy's API business manufactures and supplies high-quality, affordable Active Pharmaceutical Ingredients (APIs) to generic formulations manufacturers in 80+ countries. The company offers 250+ APIs with focus on first-to-market and hard-to-make molecules, supported by cGMP (ICH Q7) compliant manufacturing across 8 sites globally (6 in India, 1 in Mexico, 1 in UK) and 2,000+ Drug Master Files filed worldwide.
Is Dr. Reddy's Active Pharmaceutical Ingredients a public or private company?
Dr. Reddy's Active Pharmaceutical Ingredients is a public company. It is classified as public and is currently operating.
When was Dr. Reddy's Active Pharmaceutical Ingredients founded?
Dr. Reddy's Active Pharmaceutical Ingredients was founded in 1984. It employs 51 to 100 people.
Where is Dr. Reddy's Active Pharmaceutical Ingredients based?
Dr. Reddy's Active Pharmaceutical Ingredients is headquartered in Hyderabad, India, in the Asia region.
How does Dr. Reddy's Active Pharmaceutical Ingredients make money?
Four revenue lines are on record. API Sales are the primary driver. The others are generic Formulations (B2B), discovery & CDMO Services (Aurigene) and strategic Alliances.
Who are Dr. Reddy's Active Pharmaceutical Ingredients's main competitors?
Broad incumbents on record are Cipla Limited, Sun Pharmaceutical Industries, Lupin Limited, Teva Pharmaceutical Industries and Sandoz Group. Direct peers are Divi's Laboratories, Aurobindo Pharma, Laurus Labs and Aarti Pharmalabs. Piramal Pharma Limited is listed as an emerging player.
Does Dr. Reddy's Active Pharmaceutical Ingredients have an API?
No public API is recorded for Dr. Reddy's Active Pharmaceutical Ingredients.
What industry is Dr. Reddy's Active Pharmaceutical Ingredients in?
Dr. Reddy's Active Pharmaceutical Ingredients's product category is Active Pharmaceutical Ingredients Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 3254 and its SIC code is 2833.